Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05896228 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial
NCT05896228 · ClinicalTrials.gov record · last posted 2026-03-11

Iberdomide, Daratumumab, Carfilzomib, and Dexamethasone (Iber-KDd) in Patients With Relapsed/Refractory Multiple Myeloma

Study acronym: Iber-KDd
StatusRecruiting
PhasePhase 2
Started2024-02-20
View on ClinicalTrials.gov ↗
from the ClinicalTrials.gov record
The investigators want to find out whether or not giving patients who have relapsed or refractory multiple myeloma (MM) the experimental medication combination iberdomide, carfilzomib, daratumumab, and dexamethasone (Iber-KDd) may produce better results than the current (standard of care) treatments. This study will examine the tolerability and efficacy of this combination therapy for all participants and the ability of this combination therapy to shrink or prevent MM from returning.

Amendment record 10 amendments on the ClinicalTrials.gov record

This ClinicalTrials.gov record has been amended 10 times since 2023-05-31; most recent amendment 2026-03-09. DataLookout shows field-level changes from the day a trial enters its daily monitoring; earlier amendments are counted here from the ClinicalTrials.gov version history. See every version on ClinicalTrials.gov ↗

2023-10-30
Status change Not Yet Recruiting→Recruitingv4
Trial Details
NCT Number NCT05896228
Lead Sponsor Benjamin T Diamond, MD
Collaborators: Bristol-Myers Squibb
Conditions Refractory Multiple Myeloma, Relapsed Multiple Myeloma
Enrollment 30 participants
Start Date 2024-02-20
Primary Completion 2029-03-01 (estimated)
Study Completion 2031-03-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-11